Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P57730
UPID:
CAR18_HUMAN
Alternative names:
Caspase-1 inhibitor Iceberg
Alternative UPACC:
P57730; A2RRF8
Background:
Caspase recruitment domain-containing protein 18, also known as Caspase-1 inhibitor Iceberg, plays a crucial role in the immune response. It inhibits the generation of IL-1-beta by interacting with caspase-1 and preventing its association with RIP2, thereby down-regulating the release of IL1B.
Therapeutic significance:
Understanding the role of Caspase recruitment domain-containing protein 18 could open doors to potential therapeutic strategies.